Skip to main content

Table 1 MPIs of the HIV-1 Envs to MVC, VVC and TAK-779

From: A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Env MVC VVC TAK-779
  MPI SEM 95% CI Resistance phenotype MPI SEM 95% CI Resistance phenotype MPI SEM 95% CI Resistance phenotype
17-Sens 99.7 2.1 99.5-103.9 Sensitive 100.5 2.0 96.2-104.7 Sensitive 99.2 2.6 93.7-104.7 Sensitive
17-Res 91.4 1.3 88.7-94.1 Weakly Resistant 98.3 1.9 94.4-102.2 Sensitive 97.2 5.4 85.9-108.5 Sensitive
24-Sens 100.1 1.5 97.1-103.1 Sensitive 99.4 2.0 95.2-103.6 Sensitive 97.5 1.6 94.2-100.7 Sensitive
24-Res 12.5 2.5 7.3-17.6 Strongly Resistant 91.4 2.2 86.9-96.0 Weakly Cross-resistant 94.7 2.3 89.9-99.5 Weakly Cross-resistant
  1. MPIs were determined in NP2-CD4/CCR5 cells, and are calculated from 3 (VVC, TAK-779) or 5 (MVC) independent experiments.
  2. MPI, maximal percent inhibition; SEM, standard error of the mean; CI, confidence interval; MVC, maraviroc; VVC, vicriviroc.